Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 7/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 5/20 | 0.34 |
| ▸ | DRD3 | P35462 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348513 | 0.85 | GRM2 (0.37) | GRM2CD274PDCD1LG2PDCD1 | |
| SCHEMBL29348896 | 0.81 | CRBN (0.43) | GRM2 | |
| SCHEMBL31068254 | 0.81 | CRBN (0.43) | GRM2 | |
| SCHEMBL29348519 | 0.80 | HCRTR2 (0.38) | GRM2CD274PDCD1LG2PDCD1 | |
| SCHEMBL29348413 | 0.77 | CD274 (0.37) | CD274PDCD1LG2DRD2PDCD1 | |
| SCHEMBL29348489 | 0.77 | CD274 (0.33) | GRM2CD274PDCD1LG2PDCD1 | |
| SCHEMBL29348345 | 0.76 | CD274 (0.34) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL29348634 | 0.76 | CRBN (0.42) | GRM2 | |
| SCHEMBL29348526 | 0.76 | ROCK2 (0.35) | CD274PDCD1LG2 | |
| SCHEMBL29348360 | 0.75 | PDCD1LG2 (0.39) | CD274PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |